Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266814 | 0.76 | KCNA3 (0.47) | HRH3TAAR1ALDH1A1 | |
| SCHEMBL3268390 | 0.76 | KCNA3 (0.52) | HRH3KCNH2SMN1; SMN2LMNATAAR1 | |
| SCHEMBL3272371 | 0.75 | KCNA3 (0.50) | HRH3 | |
| SCHEMBL3266595 | 0.74 | KCNA3 (0.44) | HRH3LMNATAAR1ALDH1A1 | |
| SCHEMBL3272351 | 0.74 | HTR2C (0.63) | CYP2D6CYP3A4CYP2C9HRH3HRH4 | |
| SCHEMBL3272705 | 0.72 | CHRNA7 (0.44) | CYP2D6CYP3A4CYP2C9HRH3HRH4 | |
| SCHEMBL7445422 | 0.72 | HRH1 (0.58) | CYP2D6CYP3A4CYP2C9HRH3HRH4 | |
| SCHEMBL16440211 | 0.72 | NPC1 (0.40) | CYP2D6CYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL3266761 | 0.71 | TDP1 (0.49) | HRH3HRH1SMN1; SMN2 | |
| SCHEMBL3270455 | 0.71 | HTR2A (0.46) | CYP2D6CYP3A4CYP2C9HRH1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | CYP2D6 75/4885CYP3A4 295/4885CYP2C9 488/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | CYP2D6 75/4885CYP3A4 295/4885CYP2C9 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.